secwatch.observer — SEC 8-K summary
======================================

Issuer:     SANGAMO THERAPEUTICS, INC (SGMO)
CIK:        0001001233
Form:       8-K
Filed at:   2024-12-10T23:59:59+00:00
Accession:  0001628280-24-050545
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sangamo: Phase 3 hemophilia A gene therapy succeeds; share authorization suit resolved
--------------------------------------------------------------------------------

- Phase 3 AFFINE trial met primary endpoint: mean ABRtotal reduced from 4.73 (prophylaxis) to 1.24 post infusion (p=0.004).
- 84% of participants (42/50) achieved FVIII activity >5% at Month 15; 88% had no treated bleeds.
- Safety: no FVIII inhibitors, no treatment-related malignancies; ALT elevations manageable with corticosteroids.
- Delaware Court validated share increase vote standard; Sangamo dismissed Section 205 application.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001233/000162828024050545/0001628280-24-050545-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001233/000162828024050545/sgmo-20241209.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-050545

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer